Active, not recruitingPhase 2NCT02628067

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Studying Epithelial tumor of anal canal

Last synced from ClinicalTrials.gov May 8, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Merck Sharp & Dohme LLC
Principal Investigator: Medical Director
Merck Sharp & Dohme LLC
Intervention: pembrolizumab(biological)
Enrollment: 1609 enrolled
Eligibility: 18 years · All sexes
Timeline: 2015 – 2027

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02628067 on ClinicalTrials.gov

Other trials for Epithelial tumor of anal canal

Additional recruiting or active studies for the same condition.

RECRUITINGNCT05663502
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
AIDS Malignancy Consortium

See all trials for Epithelial tumor of anal canal →

← Back to all trials